search
  • Country
    Clear
  • Type
  • Compatibility Level
  • Thematic
  • Jurisdiction
4,248 Data sources

  • PL
  • NL
  • IT
  • RO

  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • more_vert
  • more_vert
  • more_vert
  • APICURON is a database to credit and acknowledge the work of biocurators, it collects and aggregates biocuration events from third party resources and generates achievements and leaderboards.

    more_vert
  • more_vert
  • more_vert
  • more_vert
  • This site provides access to the research output of the institution. The interface is available in Italian and English. Some content is not available as Full-Text.

    more_vert
  • This site provides access to the output of the University of Sassari and of research centres of North Sardinia. Some items are not available as full-text, such items are clearly marked. The interface is available in Italian or English.

    more_vert
  • chevron_left
  • 5
  • 6
  • 7
  • 8
  • 9
  • chevron_right
4,248 Data sources
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • more_vert
  • more_vert
  • more_vert
  • APICURON is a database to credit and acknowledge the work of biocurators, it collects and aggregates biocuration events from third party resources and generates achievements and leaderboards.

    more_vert
  • more_vert
  • more_vert
  • more_vert
  • This site provides access to the research output of the institution. The interface is available in Italian and English. Some content is not available as Full-Text.

    more_vert
  • This site provides access to the output of the University of Sassari and of research centres of North Sardinia. Some items are not available as full-text, such items are clearly marked. The interface is available in Italian or English.

    more_vert
  • chevron_left
  • 5
  • 6
  • 7
  • 8
  • 9
  • chevron_right